Posted in | News | Biosensors

OrSense’s NBM200 Employs Occlusion Spectroscopy Technology for Monitoring Anemia and Postnatal Hemorrhage

OrSense, a manufacturer of non-intrusive sensing devices for blood parameter measurements, has launched a non-intrusive hemoglobin (Hb) calibration device called the NBM200 for use in hemorrhage identification and anemia testing at the Barcelona-based Global Forum of Maternal and Infant Health in Spain.

OrSense has proved that the Hb counts achieved by the new non-invasive NBM200 provided precise results in comparison with the invasive point of care (POC) tools.

Anemia is the major cause of postnatal hemorrhage leading to maternal deaths and also resulting in reduced birth weights in the newborns.

OrSense has devised and marketed a non-intrusive, mobile point of care (POC) measuring device for monitoring spot and the constant hemoglobin as well as various other blood constituents. The improved device furnishes precise, secure, speedy, operation and convenient solution for testing and measurement of anemia. The non-invasive tool avoids the complicated biochemical blood examinations and finger prickings, protects from various infections and excludes the necessity of bio-hazardous substances required for such tests.

By employing this method prior examination of the chances of postnatal hemorrhage as well as enhanced post delivery management of the blood can be attained. It also strengthens maternal health status by furnishing the required web-based data, avoids the safety hazards and lowers the cost of protection. The device is CE and CDN authorized and has been proposed for the FDA 510(k) approval. The working of the device is based on the company’s patented Occlusion Spectroscopy technology, which employs a non-intrusive optical calibration base coupled with a ring-structured pneumatic sensor that can be positioned on the fingers.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    OrSense. (2019, February 25). OrSense’s NBM200 Employs Occlusion Spectroscopy Technology for Monitoring Anemia and Postnatal Hemorrhage. AZoSensors. Retrieved on June 14, 2024 from https://www.azosensors.com/news.aspx?newsID=1220.

  • MLA

    OrSense. "OrSense’s NBM200 Employs Occlusion Spectroscopy Technology for Monitoring Anemia and Postnatal Hemorrhage". AZoSensors. 14 June 2024. <https://www.azosensors.com/news.aspx?newsID=1220>.

  • Chicago

    OrSense. "OrSense’s NBM200 Employs Occlusion Spectroscopy Technology for Monitoring Anemia and Postnatal Hemorrhage". AZoSensors. https://www.azosensors.com/news.aspx?newsID=1220. (accessed June 14, 2024).

  • Harvard

    OrSense. 2019. OrSense’s NBM200 Employs Occlusion Spectroscopy Technology for Monitoring Anemia and Postnatal Hemorrhage. AZoSensors, viewed 14 June 2024, https://www.azosensors.com/news.aspx?newsID=1220.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.